Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Septerna, Inc. (SEPN)
NASDAQ:SEPN
SEPN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.17 - $28.99
Previous CloseN/A
Volume49.14K
Average Volume (3M)606.42K
Market Cap
$261.53M
Enterprise ValueN/A
Total Cash (Recent Filing)30.61M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,402,740
10 Day Avg. Volume1,361,939
30 Day Avg. Volume606,417
Standard Deviation0.18
R-Squared0.17
Alpha-0.12
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1632.02
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.00Price Target Upside141.38% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Septerna, Inc. News
PremiumCompany Announcements
Septerna, Inc. Reports Q3 2024 Financials and Progress
---
Bulls Say, Bears Say
Bulls Say
Financial StabilitySEPN ended 3Q24 with ~$440MM in pro forma cash post IPO. The company believes this provides cash runway into 2H27.
Technology And InnovationSepterna is developing novel oral small molecule GPCR-targeted drugs, utilizing a proprietary technology that captures GPCRs in their native conformational states.
Bears Say
Program DiscontinuationSEPN plans to discontinue their SEP-786 program due to unanticipated increases in unconjugated serum bilirubin.
---
Ownership Overview
24.41% Insiders
0.29% Mutual Funds
― Other Institutional Investors
73.30% Public Companies and
Individual Investors
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $4.17 and its highest was $28.99 in the past 12 months.
What is Septerna, Inc.’s market cap?
Septerna, Inc.’s market cap is $261.53M.
When is Septerna, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Septerna, Inc.’s earnings last quarter?
Septerna, Inc. released its earnings results on Nov 20, 2024. The company reported -$8.4 earnings per share for the quarter, missing the consensus estimate of -$5.877 by -$2.523.
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 44,402,740 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Septerna, Inc. reported an EPS of -$8.4 in its last earnings report, missing expectations of -$5.877. Following the earnings report the stock price went down -7.025%.
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
---
Septerna, Inc. Stock Smart Score
Company Description
Septerna, Inc.
Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Our lead product candidate, SEP-786, is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. We have successfully completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of SEP-786.
---
SEPN Stock 12 Month Forecast
Average Price Target
$14.00
▲(141.38% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Biogen
―
Ionis Pharmaceuticals
―
Regeneron
―
Vertex Pharmaceuticals
―
Best Analysts Covering SEPN
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-76.00%
initiated a buy rating 3 months ago
Copying Joshua Schimmer's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -76.00% per trade.
---